specifically to measure areas of executive function will be utilized, as well as role-playing tasks thought to have good ecological validity. Symptoms of psychosis will also be assessed. GMT will be administered in 9 (twice weekly) x 2 hour sessions in accordance with the GMT research protocol. A general linear model with repeated measures analysis of variance (RM ANOVA) will be used to examine differential group treatment effects. A 2 x 3 mixed-design will be applied, with Group (GMT, WL) as betweensubjects factor, and Session (baseline [T1], post-intervention [T2], and 6 months follow-up [T3]) as within-subjects factor. Interpretation of the strength of experimental effects will be provided with effect size statistics. Results: Baseline characteristics and preliminary results from the first participants will be presented. Discussion: Based on findings from previous GMT-studies, we hypothesize that post-intervention changes will be reflected in improved scores on selfreported and/or objective measures of executive functions (particularly in the areas of planning and attentional control) compared to patients in WL. We also expect that GMT participants will improve their goal attainment in everyday life and social functioning after the intervention. Additionally, we expect post-intervention changes to be reflected in improved scores on measures of emotional health. Background: CoQ10 is a vital component of mitochondrial function and metabolism, and its deficiency creates greater vulnerability to disease due to impaired mitochondrial energy generation and cellular antioxidant capacity. CoQ10 functions as an electron carrier within the mitochondrial electron transport chain during cellular respiration. Schizophrenia is a disorder with documented CoQ10 deficiency and mitochondrial dysfunction, and cellular respiration and mitochondrial network dynamics can be impaired due to altered complex 1 activity in the disorder. Key features of schizophrenia such as depression, fatigue and cognitive impairment have been independently associated with mitochondrial dysfunction and increased oxidative stress. In bipolar disorder, fibromyalgia, chronic fatigue syndrome and multiple sclerosis these symptoms have been effectively reduced through CoQ10 supplementation. We assess the impact of CoQ10 supplementation in individuals with a diagnosis of schizophrenia through a double-blind, randomised, placebo-controlled study.
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Background: CoQ10 is a vital component of mitochondrial function and metabolism, and its deficiency creates greater vulnerability to disease due to impaired mitochondrial energy generation and cellular antioxidant capacity. CoQ10 functions as an electron carrier within the mitochondrial electron transport chain during cellular respiration. Schizophrenia is a disorder with documented CoQ10 deficiency and mitochondrial dysfunction, and cellular respiration and mitochondrial network dynamics can be impaired due to altered complex 1 activity in the disorder. Key features of schizophrenia such as depression, fatigue and cognitive impairment have been independently associated with mitochondrial dysfunction and increased oxidative stress. In bipolar disorder, fibromyalgia, chronic fatigue syndrome and multiple sclerosis these symptoms have been effectively reduced through CoQ10 supplementation. We assess the impact of CoQ10 supplementation in individuals with a diagnosis of schizophrenia through a double-blind, randomised, placebo-controlled study.
Methods: Approximately 300 participants with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder, with no neurological or psychiatric co-morbidity will be recruited to this study. Participants will be randomised to take 100 mg dose capsules of CoQ10 or placebo three times daily for six months, and undergo neuropsychological and cognitive testing at three time points (baseline, midpoint, six months post-randomisation). Changes in participants' global cognitive function, sustained attention, working memory, processing speed, negative symptoms, levels of depression and anxiety, fatigue, blood pressure, quality of life and functional status following CoQ10 supplementation will be assessed. Blood samples are also taken at each assessment session to assess baseline and changes in levels of plasma CoQ10 and mitochondrial function via lactate analysis.
Results: Currently baseline data is available for 42 participants (mean age = 50.2, SD=10.7). All participants either have a clinical diagnosis of schizophrenia (n=34) or schizoaffective disorder (n=8). The mean estimated IQ of the group is 92.4 (SD=20.5), and participants have a median of 13 years in education. Thirty-nine percent of participants reported mild to severe levels of depression and twenty-three percent reported moderate or severe levels of anxiety. Seventy-three percent of participants reported good to very good quality of life. FACIT-fatigue scores were negatively correlated with both depression and anxiety scores, such that greater fatigue levels were associated with higher levels of depression (r=-.484, p<0.01) and anxiety (r=-.539, p<0.01). Discussion: CoQ10 is a mitochondrial agent that plays a fundamental role in energy production and mitochondrial function. The available baseline data suggest a relationship between fatigue and depression and anxiety levels in individuals with a diagnosis of schizophrenia. CoQ10 supplementation has the potential to affect these symptoms, through CoQ10's ability to restore electron flow in the electron transfer chain and increase mitochondrial antioxidant capacity. The study commenced in November 2016 and patient enrolment and assessment is ongoing. Updated baseline information will be presented including further cognitive assessments. To minimise risk of bias while recruitment and assessments are ongoing, unblinding and outcome analysis will not be conducted at time of presentation. Background: Resilience provides a new understanding of the highly variable trajectories of mental illness, and has consistently been linked with improved mental health outcomes. Resilience is largely defined as the presence of additional factors which overcome a specific risk for mental illness, leading to ultimately more positive outcomes than expected given said risk. Previous research in the area has focused on identifying psychological factors which may be associated with resilience. Moving forwards, it is essential that researchers investigate how resilience may function in different domains. The aim for the present research was to conduct a preliminary investigation into the possible role of neuropsychological performance in resilience using data from the PRONIA study. Methods: Participants were individuals aged 15-40 who were recruited into the PRONIA study. Total scores for the Resilience Scale for Adults (RSA), assessing self-report psychological resilience, were available for 587 participants. The sample included individuals with first-episode psychosis (N=113), first-episode depression (N=118), individuals at ultra-high risk for psychosis (N=109), and healthy controls (N=247). Participants also completed a comprehensive neuropsychological test battery which assessed performance in the following domains: IQ, executive functioning (EF), processing speed (PS), sustained attention, working memory, visual memory, social cognition, motivational salience, and verbal learning and memory. Results: A stepwise multiple linear regression was used to identify which of the neuropsychological domains would best predict RSA total score. The final model significantly predicted RSA total score, explaining 4% of the variance in these scores, F(2, 512) = 12.37, p < 0.001. The model indicated that higher RSA total was associated with PS (β=3.35, p=.032) and EF (β=4.15, p=0.046) . EF provided the highest relative contribution in the model, with every 1 point increase resulting in 4.15 standard deviation increase in RSA total. Discussion: The present results suggest that neuropsychological performance has a small, but significant relationship with psychological resilience. The two neuropsychological domains which best predicted this outcome were PS and EF. Resilience has been argued to be a highly dynamic process, by which individuals must utilise assets and resources to their benefit. Furthermore, the effectiveness of such factors will vary across time and circumstance, adding to the flexibility required to navigate this process. These results support this conceptualisation of resilience, as EF is thought to involve the organisation and execution of complex thoughts and behaviour. Processing speed has also been found to affect other cognitive functions
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